ID: ALA3234429

Max Phase: Preclinical

Molecular Formula: C2H7O3PS

Molecular Weight: 142.12

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  O=P(O)(O)CCS

Standard InChI:  InChI=1S/C2H7O3PS/c3-6(4,5)1-2-7/h7H,1-2H2,(H2,3,4,5)

Standard InChI Key:  TXCBWQYWCDOLHF-UHFFFAOYSA-N

Associated Targets(non-human)

Fe(3+)-Zn(2+) purple acid phosphatase 65 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 142.12Molecular Weight (Monoisotopic): 141.9854AlogP: 0.09#Rotatable Bonds: 2
Polar Surface Area: 57.53Molecular Species: ACIDHBA: 2HBD: 3
#RO5 Violations: 0HBA (Lipinski): 3HBD (Lipinski): 2#RO5 Violations (Lipinski): 0
CX Acidic pKa: 1.80CX Basic pKa: CX LogP: -0.93CX LogD: -3.29
Aromatic Rings: 0Heavy Atoms: 7QED Weighted: 0.38Np Likeness Score: 0.37

References

1. McGeary RP, Schenk G, Guddat LW..  (2014)  The applications of binuclear metallohydrolases in medicine: recent advances in the design and development of novel drug leads for purple acid phosphatases, metallo-β-lactamases and arginases.,  76  [PMID:24583353] [10.1016/j.ejmech.2014.02.008]

Source